This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
2021 Southeastern Section of the American Urological Association
Viewing 1-16 of 16 articles
SES AUA 2021: Prostate Biopsy in 2021 - What is Current Best Practice?
SES AUA 2021: Prostate Cancer: Genetics and Markers
SES AUA 2021: Modern Bladder Cancer Warfare: Does "Leave No Bladder Behind" Ethos Still Apply?
SES AUA 2021: Contemporary Management of Advanced Prostate Cancer - Decisions Based on Precision and Better Ammunition
SES AUA 2021: Ambrose Reed Lecture: May I Have This Dance? The Importance of Diversity and Inclusion in Urology
SES AUA 2021: Financial Toxicity in Urologic Oncology
SES AUA 2021: Quality Metrics for the Urologist
SES AUA 2021: Imaging in Prostate Cancer: Shiny New Things
SES AUA 2021: A Comparison of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to Preoperatively Differentiate Benign from Malignant Renal Masses
SES AUA 2021: Results from Targeted Germline Sequencing in Men on Active Surveillance for Prostate Cancer
SES AUA 2021: Does MRI Demonstrate Racial Differences in Prostate Cancer Lesions by Zone?
SES AUA 2021: Genetic Testing in Prostate Cancer - Understanding the Implications for Early Detection, Localized Disease & Castration-Resistant Prostate Cancer
SES AUA 2021: miRNA-301A: A Potential Health Disparity Marker in Men with Prostate Cancer
SES AUA 2021: Objective Risk Score Reliably Predicts Mortality After Radical Nephrectomy
SES AUA 2021: The Critical Pursuit of Social Justice in Urology
SES AUA 2021: Avelumab First-Line Maintenance + Best Supportive Care (BSC) vs BSC Alone with 1L Chemotherapy for Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analyses
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free